EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study

Lisa Wein, Carolin Ertl, Theresa Ruf, Monika Morak, Ying Wang, Christina Schmitt, Xiomara Garza Vazquez, Valerie Glatzel, Richard David-Rus, Mohammed Mitwalli, Jerome Srour, Pia Schöpf und 3 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2026-015185 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Lisa Wein und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Immune Checkpoint Inhibitors, Immunosuppression Therapy, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Foundation Immunooncology, Dr. Sepp and Hanne Sturm Memorial Foundation, Verein zur Foerderung des Tumorzentrums der Universitaet Erlangen-Nuernberg e.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor-induced immune-related adverse events (irAEs) can be steroid-refractory (sr) or steroid-dependent (sd), requiring second-line therapy. Evidence guiding optimal management of sr/sd-irAEs while preserving antitumor efficacy is scarce. This study compared extracorporeal photopheresis (ECP) with systemic immunosuppressants (IS) for treatment of sr/sd-irAEs.

Methods

This prospective two-arm study included 46 patients (23 ECP, 23 IS) with 12 distinct types of irAEs across 6 tumor entities, all classified as steroid-refractory or steroid-dependent. Toxicities affected the gastrointestinal tract, skin, lung, musculoskeletal system, and serosal membranes, with up to seven prior irAE treatment lines. Patients received six cycles of ECP or investigator’s choice IS over 12 weeks. Longitudinal assessments included clinical irAE outcomes, quality of life (QoL), and tumor response. ECP was more frequently used in patients with multi-toxicity (39% vs 9%; p=0.02) and multi-resistance to prior second-line immunosuppression (39% vs 17%; p=0.19).

Results

At week 12, ECP showed a lower cumulative corticosteroid exposure (395 mg vs 1,260 mg prednisolone equivalent; p=0.03), significantly improved QoL (p=0.01), and a numerically higher irAE response rate without statistical significance compared with IS (94% vs 81%; p=0.85). In advanced cutaneous melanoma, ECP was associated with superior overall survival (15 vs 10 months; p=0.02), and longer progression-free survival (9 vs 3 months; p=0.01). No significant safety concerns were observed with ECP; one fatality in the IS group was infection-related.

Conclusions

ECP demonstrated clinical outcomes comparable to IS in sr/sd-irAEs, with significantly lower cumulative corticosteroid exposure and improved QoL. Furthermore, ECP was associated with a favorable safety profile and showed no evidence of compromised antitumor activity. A multicenter trial is planned for further investigation. Trial registration number NCT05700565 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsImmunosuppression TherapyImmunosuppressive AgentsNeoplasmsPhotopheresisAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmune related adverse event - irAEQuality of life - QOL

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany.
  • Institute of Anthropology Francisc I. Rainer, Romanian Academy, Bucharest, Romania.
  • Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
  • Dr. Philip Frost, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany lucie.heinzerling@med.uni-muenchen.de.
  • Department of Dermatology and Allergology, FAU, Erlangen, Germany.

Förderung

  • German Foundation Immunooncology
  • Dr. Sepp and Hanne Sturm Memorial Foundation
  • Verein zur Foerderung des Tumorzentrums der Universitaet Erlangen-Nuernberg e.V.
  • German Federal Ministry of Education and Research

Zitieren

APA

Wein, L., Ertl, C., Ruf, T., Morak, M., Wang, Y., Schmitt, C., Garza Vazquez, X., Glatzel, V., David-Rus, R., Mitwalli, M., Srour, J., Schöpf, P., Tomsitz, D., French, L. E., & Heinzerling, L. (2026). Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-015185

Vancouver

Wein L, Ertl C, Ruf T, Morak M, Wang Y, Schmitt C, et al. Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-015185

BibTeX
@article{Wein2026,
  author = {Wein, Lisa and Ertl, Carolin and Ruf, Theresa and Morak, Monika and Wang, Ying and Schmitt, Christina and Garza Vazquez, Xiomara and Glatzel, Valerie and David-Rus, Richard and Mitwalli, Mohammed and Srour, Jerome and Schöpf, Pia and Tomsitz, Dirk and French, Lars E and Heinzerling, Lucie},
  title = {Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2026-015185}
}
Kostenlos starten →